Charles River Laboratories (CRL) Tops Q1 EPS by 19c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $332.44 -5.52%
Financial Fact:
Cost of services provided: 200.12M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Cost of services provided: 200.12M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.78, $0.19 better than the analyst estimate of $2.59. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $986.31 million.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $9.90-$10.90, versus the consensus of $10.24.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Charles River Laboratories (CRL) Tops Q3 EPS by 12c ; Offers Guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
